Cancer Letters
Volume 286, Issue 2 , Pages 196-205 , 28 December 2009

Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-β expression driven by hTERT promoter

  • Ling Feng He

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • Laboratory of Cancer Therapy, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    • Ling Feng He and Yi Gang Wang contributed equally to this paper.
    • ,
  • Yi Gang Wang

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China
    • Ling Feng He and Yi Gang Wang contributed equally to this paper.
    • ,
  • Tian Xiao

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • ,
  • Kang Jiang Zhang

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • ,
  • Gong Chu Li

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • ,
  • Jin Fa Gu

      Affiliations

    • Laboratory of Cancer Therapy, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    • ,
  • Liang Chu

      Affiliations

    • Laboratory of Cancer Therapy, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    • ,
  • Wen Hao Tang

      Affiliations

    • Huadong Hospital of Fudan University, Shanghai 200040, China
    • ,
  • Wen-Song Tan

      Affiliations

    • State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China
    • Corresponding Author InformationCorresponding authors. Address: Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, China. Fax: +86 571 86843185, +86 21 54921126 (X.Y. Liu), tel.: +86 21 64250948; fax: +86 21 64252250 (W.-S. Tan).
    • ,
  • Xin Yuan Liu

      Affiliations

    • Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China
    • Laboratory of Cancer Therapy, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    • Corresponding Author InformationCorresponding authors. Address: Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, China. Fax: +86 571 86843185, +86 21 54921126 (X.Y. Liu), tel.: +86 21 64250948; fax: +86 21 64252250 (W.-S. Tan).

Received 24 November 2008 ,Revised 23 April 2009 ,Accepted 25 May 2009.

References 

  1. Pfeffer LM, Dinarello CA, Herberman RB. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489–2499
  2. Sondak VK. How does interferon work? Does it even matter?. Cancer. 2002;95:947–949
  3. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer. 2004;4:11–22
  4. Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest. 2001;108:83–95
  5. Nehashi K, Yoshida J, Wakabayashi T, Nagata M, Utsumi J, Naruse N, et al. Growth inhibition of human glioma cells by superinduced human interferon-β. Neurol. Med. Chir. 1995;35:719–722(Tokyo)
  6. Kaynor C, Xin M, Wakefield J, Barsoum J, Qin XQ. Direct evidence that IFN-beta functions as a tumor-suppression protein. J. Interferon Cytokine Res. 2002;22:1089–1098
  7. Odaka M, Wiewrodt R, DeLong P, Tanaka T, Zhang Y, Kaiser L, et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol. Ther. 2002;6:210–218
  8. Tanabe T, Kominsky SL, Subramaniam PS, Johnson HM, Torres BA. Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1). J. Neurooncol. 2000;48:225–232
  9. Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC, Davidoff AM. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett. 2005;228:163–170
  10. He LF, Gu JF, Tang WH, Fan JK, Wei N, Zou WG, et al. Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J. Gene Med. 2008;10:983–992
  11. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci. 2006;97:57–63
  12. Streck CJ, Dickson PV, Ng CY, Zhou J, Hall MM, Gray JT, et al. Antitumor efficacy of AAV mediated systemic delivery of interferon-beta. Cancer Gene Ther. 2006;13:99–106
  13. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy?. J. Interferon Cytokine Res. 1996;16:275–281
  14. Salmon P, Le Cotonnec JY, Galazka A, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res. 1996;16:759–764
  15. Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose; an open pilot study. Neurosurgery. 1996;38:1096–1103
  16. Streck CJ, Dickson PV, Ng CY, Zhou J, Gray JT, Nathwani AC, et al. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin. Cancer Res. 2005;11:6020–6029
  17. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003;348:255–256
  18. Muruve DA. The innate immune response to adenovirus vectors. Hum. Gene Ther. 2004;15:1157–1166
  19. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006;14:316–327
  20. Wang YG, Huang F, Cai R, Qian C, Liu XY. Targeting strategies for adeno-associated viral vector. Chin. Sci. Bull. 2007;52:1590–1599
  21. Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J. Neurosur. 2006;104:583–592
  22. Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, Blackwell JL, et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001;8:990–996
  23. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999;59:551–557
  24. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene. 2002;21:8020–8028
  25. Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene. 2002;23:457–464
  26. Liu J, Zou WG, Lang MF, Luo J, Sun LY, Wang XN, et al. Cancer specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int. J. Oncol. 2002;21:661–666
  27. Wang Y, Huang F, Cai H, Tan WS, Liu XY. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J. Gene Med. 2008;10:518–526
  28. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 2008;82:1154–1161
  29. Wang YG, Wang JH, Zhang YH, Gu Q, Liu XY. Antitumor effect of a novel adeno-associated virus vector targeting to telomerase activity in tumor cells. Acta Biochim. Biophys. Sin. 2004;36:492–500
  30. Benjamin R, Khwaja A, Singh N, McIntosh J, Meager A, Wadhwa M, et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood. 2007;109:1244–1247
  31. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 2005;16:541–550
  32. Zhang H, Koty PP, Mayotte J, Levitt ML. Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp. Cell Res. 1999;247:133–141
  33. Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, et al. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res. 2005;65:8379–8387
  34. Saudan P, Vlach J, Beard P. Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO J. 2000;19:4351–4361
  35. Nakamoto N, Higuchi H, Kanamori H, Kurita S, Tada S, Takaishi H, et al. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo. Int. J. Oncol. 2006;29:625–635
  36. Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G. Study of the effects of interferon on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int. 2004;24:149–160
  37. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cell. 1996;14:239–248
  38. Ramirez RD, Wright WE, Shay JW, Taylor RS. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J. Invest. Dermatol. 1997;108:113–117
  39. Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, et al. Telomerase activity in normal human epithelial cells. Oncogene. 1996;13:433–439
  40. Bodnar AG, Kim NW, Effros RB, Chiu CP. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 1996;228:58–64
  41. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues, CA. Cancer J. Clin. 2008;58:161–179
  42. Hamner JB, Sims TL, Cutshaw A, Dickson PV, Rosati S, McGee M, et al. The efficacy of combination therapy using adeno-associated virus-interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma. J. Pediatr. Surg. 2008;43:177–183
  43. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-β pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J. Immunol. 2002;169:847–855

PII: S0304-3835(09)00381-4

doi: 10.1016/j.canlet.2009.05.024

Cancer Letters
Volume 286, Issue 2 , Pages 196-205 , 28 December 2009

Article Tools

* Image Usage & Resolution